CN105535636A - Medicinal composition for treating liver-yang hyperactivity type hypertension - Google Patents
Medicinal composition for treating liver-yang hyperactivity type hypertension Download PDFInfo
- Publication number
- CN105535636A CN105535636A CN201610040872.XA CN201610040872A CN105535636A CN 105535636 A CN105535636 A CN 105535636A CN 201610040872 A CN201610040872 A CN 201610040872A CN 105535636 A CN105535636 A CN 105535636A
- Authority
- CN
- China
- Prior art keywords
- parts
- liver
- yang
- medicinal composition
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicinal composition for treating liver-yang hyperactivity type hypertension. The medicinal composition is prepared from the following raw materials in parts by weight: 7-15 parts of dragon bone, 9-16 parts of oyster, 6-13 parts of lycium barbarum, 5-13 parts of sesamum indicum, 3-11 parts of selfheal, 5-10 parts of chrysanthemum, 3-8 parts of corn stigma, 6-13 parts of tuber fleeceflower stems, 3-10 parts of tribulus terrestris and 5-12 parts of lotus seeds. The components of the medicinal composition play roles of coordination, can help one another and can take the effects of clearing heat and removing dysphoria, calming the liver and suppressing yang, nourishing yin to lessen fire as well as dispelling the wind and activating blood, the results of clinical tests in five years show that the medicinal composition is remarkable in treatment effect, rapid to take the effect into play, low in reoccurrence rate and free of toxic or side effect when being used for treating liver-yang hyperactivity type hypertension, the results of tests on 90 cases of patients show that the effective rate is up to 95.6%, and the disease does not reoccur within one year of follow-visiting after being treated.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to one and treat the hypertensive pharmaceutical composition of liver-Yang sthenia type.
Background technology
Hypertension is one of most common cardiovascular diseases, and sickness rate is high.In recent years, unreasonable along with growth in the living standard and dietary structure, not only at Elderly patients, in Yong adult crowd, sickness rate is also in lasting rising, serious harm human health.On the basis of theory of Chinese medical science in conjunction with internal organs, the eight guiding principles for diagnosis, the cause of disease, pathogenesis, name of disease, carry out differentiation of symptoms and signs for classification of syndrome to hypertension to think, this of disease is imbalance of YIN and YANG, the wind being designated as interior life of disease, expectorant, congestion, generally can be divided into liver-Yang sthenia type, type of deficiency of YIN leading to hyper activity of YANG, deficiency of both YIN and YANG type, liver-kidney yin deficiency four pattern of syndrome and endogenous wind, blood stasis, stagnation of phlegm three accompanied symptoms.Wherein syndrome of upper hyperactivity of liver yang is the common pattern of syndrome of hypertension, accounts for more than 87%.Syndrome of upper hyperactivity of liver yang with kidney water lose under, the kidney failing to nourish the liver, and to cause the partially high or absolute high Sheng of liver-yang of liver-yang be main pathogenesis, its Symptoms is feeling of fullness in the head, headache, flushing red, bitter taste, vexed, red tongue, wiry forceful pulse.
The method of current treatment liver-Yang sthenia type hypertension, doctor trained in Western medicine is based on enalapril meleate, as calcium ion antagonist, β-receptor blocking agent, angiotensin converting enzyme inhibitor, diuretic, but enalapril meleate has certain side effect, to target organ, there is certain infringement, and have certain dependency.Tcm therapy mainly based on oral Rhizoma Gastrodiae, Ramulus Uncariae Cum Uncis medicament, is mainly started with from suppressing the hyperactive liver to relieve the wind syndrome relieving convulsion.Although this kind of prescription prescription is simple, curative effect is unsatisfactory, and obvious effective rate is not very good.
Summary of the invention
The hypertensive pharmaceutical composition curative effect of liver-Yang sthenia type is reliable, instant effect to the object of the present invention is to provide one to treat, and has no side effect.
For realizing above object, the present invention is achieved by the following technical programs:
One treats the hypertensive pharmaceutical composition of liver-Yang sthenia type, is made up of the raw material of following weight portion: Os Draconis 7-15 part, Concha Ostreae 9-16 part, Fructus Lycii 6-13 part, Semen Lini 5-13 part, Spica Prunellae 3-11 part, Flos Chrysanthemi 5-10 part, Stigma Maydis 3-8 part, Caulis Polygoni Multiflori 6-13 part, Fructus Tribuli 3-10 part, Semen Nelumbinis 5-12 part.
Preferably, the described hypertensive pharmaceutical composition for the treatment of liver-Yang sthenia type, is made up of the raw material of following weight portion: Os Draconis 9-12 part, Concha Ostreae 10-15 part, Fructus Lycii 8-11 part, Semen Lini 8-11 part, Spica Prunellae 5-9 part, Flos Chrysanthemi 7-9 part, Stigma Maydis 4-6 part, Caulis Polygoni Multiflori 8-11 part, Fructus Tribuli 5-8 part, Semen Nelumbinis 8-11 part.
Preferably, the described hypertensive pharmaceutical composition for the treatment of liver-Yang sthenia type, is made up of the raw material of following weight portion: Os Draconis 11 parts, Concha Ostreae 13 parts, Fructus Lycii 9 parts, Semen Lini 10 parts, Spica Prunellae 7 parts, Flos Chrysanthemi 8 parts, Stigma Maydis 5 parts, Caulis Polygoni Multiflori 9 parts, Fructus Tribuli 6 parts, 10 parts, Semen Nelumbinis.
Preferably, described Fructus Tribuli is salt Fructus Tribuli, and described Concha Ostreae is Concha Ostreae.
Preferably, described pharmaceutical composition is oral liquid, decoction, granule, tablet, pill or capsule.
Beneficial effect of the present invention: in the present invention, Os Draconis are calmed the nerves YANG hyperactivity suppressing, Concha Ostreae suppressing the hyperactive liver to relieve the wind syndrome, Fructus Lycii, Semen Lini nourishing the liver and kidney, benefit essence is moisturized, Spica Prunellae lets out liver-fire clearly, eliminating stagnation is eliminated the phlegm, the heat clearing away of chrysanthemum powder forimproving wind, suppressing the hyperactive liver pain relieving, Stigma Maydis expels the heat-evil diuresis, suppressing the hyperactive liver function of gallbladder promoting, Caulis Polygoni Multiflori tranquilizing by nourishing the heart, dispelling wind and removing obstruction in the collateral, Fructus Tribuli expelling wind and activating blood circulation, QI invigorating is reduced phlegm, Semen Nelumbinis clearing away heart-fire for tranquillization, all side's coordinative roles, mutually auxiliary help, play heat clearing away altogether to go to be tired of, suppressing the hyperactive liver and subsiding YANG, nourishing YIN to lower pathogenic fire, effect of expelling wind and activating blood circulation, verify through clinical experiment, treatment treatment liver-Yang sthenia type hypertension is evident in efficacy, instant effect, relapse rate is low, without any side effects, over 5 years, by showing 90 the on probation of routine patient, effective percentage reaches 95.6%, 1 year is followed up a case by regular visits to without recurrence after healing.
Detailed description of the invention
For making the object of the embodiment of the present invention, technical scheme and advantage clearly, below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described, obviously, described embodiment is the present invention's part embodiment, instead of whole embodiments.Based on the embodiment in the present invention, those of ordinary skill in the art, not making the every other embodiment obtained under creative work prerequisite, belong to the scope of protection of the invention.
Embodiment 1:
One treats the hypertensive pharmaceutical composition of liver-Yang sthenia type, is made up of the raw material of following weight portion: Os Draconis 11 parts, Concha Ostreae 13 parts, Fructus Lycii 9 parts, Semen Lini 10 parts, Spica Prunellae 7 parts, Flos Chrysanthemi 8 parts, Stigma Maydis 5 parts, Caulis Polygoni Multiflori 9 parts, salt Fructus Tribuli 6 parts, 10 parts, Semen Nelumbinis.
Described pharmaceutical composition is oral liquid, decoction, granule, tablet, pill or capsule.
Embodiment 2:
One treats the hypertensive pharmaceutical composition of liver-Yang sthenia type, is made up of the raw material of following weight portion: Os Draconis 7 parts, Concha Ostreae 16 parts, Fructus Lycii 6 parts, Semen Lini 13 parts, Spica Prunellae 3 parts, Flos Chrysanthemi 10 parts, Stigma Maydis 3 parts, Caulis Polygoni Multiflori 13 parts, salt Fructus Tribuli 3 parts, 12 parts, Semen Nelumbinis.
Described pharmaceutical composition is oral liquid, decoction, granule, tablet, pill or capsule.
Embodiment 3:
One treats the hypertensive pharmaceutical composition of liver-Yang sthenia type, is made up of the raw material of following weight portion: Os Draconis 15 parts, Concha Ostreae 9 parts, Fructus Lycii 13 parts, Semen Lini 5 parts, Spica Prunellae 11 parts, Flos Chrysanthemi 5 parts, Stigma Maydis 8 parts, Caulis Polygoni Multiflori 6 parts, salt Fructus Tribuli 10 parts, 5 parts, Semen Nelumbinis.
Described pharmaceutical composition is oral liquid, decoction, granule, tablet, pill or capsule.
Embodiment 4:
One treats the hypertensive pharmaceutical composition of liver-Yang sthenia type, is made up of the raw material of following weight portion: Os Draconis 12 parts, Concha Ostreae 10 parts, Fructus Lycii 11 parts, Semen Lini 8 parts, Spica Prunellae 9 parts, Flos Chrysanthemi 7 parts, Stigma Maydis 6 parts, Caulis Polygoni Multiflori 8 parts, salt Fructus Tribuli 8 parts, 8 parts, Semen Nelumbinis.
Case: patient's Mr. Chen, man, 42 years old, suffer from liver-Yang sthenia type hypertension 5 years, blood pressure is generally 160/100mm hydrargyrum post, Long-term Oral Western medicine depressor controls symptom, the proportioning in the present embodiment 4 is adopted to weigh the raw material of each weight portion, conventionally produce pill, oral, three times on the one, consumption 9g/ time, it within 7 days, is a course for the treatment of, after taking two courses for the treatment of, symptom is improved, blood pressure returns to 140/90mmHg, after taking medicine 1 month, systolic pressure is everlasting 100-135mmHg, diastolic pressure is at 70-90mmHg, reasonably combined diet, moderate exercise, drug withdrawal was not recurred after 1 year.
Embodiment 5:
One treats the hypertensive pharmaceutical composition of liver-Yang sthenia type, is made up of the raw material of following weight portion: Os Draconis 9 parts, Concha Ostreae 15 parts, Fructus Lycii 8 parts, Semen Lini 11 parts, Spica Prunellae 5 parts, Flos Chrysanthemi 9 parts, Stigma Maydis 4 parts, Caulis Polygoni Multiflori 11 parts, salt Fructus Tribuli 5 parts, 11 parts, Semen Nelumbinis.
Described pharmaceutical composition is oral liquid, decoction, granule, tablet, pill or capsule.
Through detection and the clinical case discovery of drug effect, the medicine effect in embodiment 1 is best.
Clinical case: select 90 routine liver-Yang sthenia type patients with hypertension, male have 58 example, women have 32 example, the age 30-55 year between.Its clinical symptoms shows as: feeling of fullness in the head, headache, flushing red, bitter taste, vexed, red tongue, wiry forceful pulse, through Measure blood pressure be: systolic pressure is at 170-140mmHg, and diastolic pressure is at 110-95mmHg.Do electrocardiogram and Abdominal B type ultrasonography inspection to all patients, check result is without exception.
Adopt pharmaceutical composition of the present invention to treat to above liver-Yang sthenia type hyperpietic, weigh the raw material of each weight portion according to the proportioning in the embodiment of the present invention 1, produce according to capsule conventional production process, every 0.5g, patient is oral, three times on the one, each 37 days is a course for the treatment of.
Curative effect judging standard: effective systolic pressure/diastolic pressure≤130/85mmHg, meanwhile, other is with clinical symptom disappearance or alleviate; Effective: systolic pressure/diastolic pressure controls at 135/85mmHg ~ 150/90mmHg, meanwhile, other is with clinical symptom disappearance or alleviate; Invalid: systolic pressure/diastolic pressure >=160/100mmHg, other is not improved with clinical symptoms.
Adopt capsule prepared by the present invention, after taking a course for the treatment of, obvious effective rate is 73.3%, and effective percentage is 16.7%, and after taking two courses for the treatment of, obvious effective rate is 87.8%, and effective percentage is 7.8%, and total effective rate is 95.6%, and inefficiency is 4.4%.
It should be noted that, in this article, the such as relational terms of first and second grades and so on is only used for an entity or operation to separate with another entity or operating space, and not necessarily requires or imply the relation that there is any this reality between these entities or operation or sequentially.And, term " comprises ", " comprising " or its any other variant are intended to contain comprising of nonexcludability, thus make to comprise the process of a series of key element, method, article or equipment and not only comprise those key elements, but also comprise other key elements clearly do not listed, or also comprise by the intrinsic key element of this process, method, article or equipment.When not more restrictions, the key element limited by statement " comprising ... ", and be not precluded within process, method, article or the equipment comprising described key element and also there is other identical element.
Above embodiment only in order to technical scheme of the present invention to be described, is not intended to limit; Although with reference to previous embodiment to invention has been detailed description, those of ordinary skill in the art is to be understood that: it still can be modified to the technical scheme described in foregoing embodiments, or carries out equivalent replacement to wherein portion of techniques feature; And these amendments or replacement, do not make the essence of appropriate technical solution depart from the spirit and scope of various embodiments of the present invention technical scheme.
Claims (5)
1. the hypertensive pharmaceutical composition for the treatment of liver-Yang sthenia type, it is characterized in that, be made up of the raw material of following weight portion: Os Draconis 7-15 part, Concha Ostreae 9-16 part, Fructus Lycii 6-13 part, Semen Lini 5-13 part, Spica Prunellae 3-11 part, Flos Chrysanthemi 5-10 part, Stigma Maydis 3-8 part, Caulis Polygoni Multiflori 6-13 part, Fructus Tribuli 3-10 part, Semen Nelumbinis 5-12 part.
2. the hypertensive pharmaceutical composition for the treatment of liver-Yang sthenia type as claimed in claim 1, it is characterized in that, be made up of the raw material of following weight portion: Os Draconis 9-12 part, Concha Ostreae 10-15 part, Fructus Lycii 8-11 part, Semen Lini 8-11 part, Spica Prunellae 5-9 part, Flos Chrysanthemi 7-9 part, Stigma Maydis 4-6 part, Caulis Polygoni Multiflori 8-11 part, Fructus Tribuli 5-8 part, Semen Nelumbinis 8-11 part.
3. the hypertensive pharmaceutical composition for the treatment of liver-Yang sthenia type as claimed in claim 2, it is characterized in that, be made up of the raw material of following weight portion: Os Draconis 11 parts, Concha Ostreae 13 parts, Fructus Lycii 9 parts, Semen Lini 10 parts, Spica Prunellae 7 parts, Flos Chrysanthemi 8 parts, Stigma Maydis 5 parts, Caulis Polygoni Multiflori 9 parts, Fructus Tribuli 6 parts, 10 parts, Semen Nelumbinis.
4. the hypertensive pharmaceutical composition for the treatment of liver-Yang sthenia type as claimed in claim 3, it is characterized in that, described Fructus Tribuli is salt Fructus Tribuli, and described Concha Ostreae is Concha Ostreae.
5. the hypertensive pharmaceutical composition for the treatment of liver-Yang sthenia type as described in as arbitrary in claim 1-4, it is characterized in that, described pharmaceutical composition is oral liquid, decoction, granule, tablet, pill or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610040872.XA CN105535636A (en) | 2016-01-21 | 2016-01-21 | Medicinal composition for treating liver-yang hyperactivity type hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610040872.XA CN105535636A (en) | 2016-01-21 | 2016-01-21 | Medicinal composition for treating liver-yang hyperactivity type hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105535636A true CN105535636A (en) | 2016-05-04 |
Family
ID=55815525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610040872.XA Pending CN105535636A (en) | 2016-01-21 | 2016-01-21 | Medicinal composition for treating liver-yang hyperactivity type hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105535636A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105726573A (en) * | 2016-05-09 | 2016-07-06 | 林荣波 | Traditional Chinese medicine composition for treating hypertension caused by liver-yang hyperactivity |
| CN109394960A (en) * | 2018-12-27 | 2019-03-01 | 李晓君 | A kind of Chinese medicine composition and preparation method thereof for treating hypertension |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526340A (en) * | 2011-12-30 | 2012-07-04 | 辽宁中医药大学附属医院 | Medicament for preventing and treating hypertension |
| CN102698092A (en) * | 2012-06-04 | 2012-10-03 | 蒋月芳 | Traditional Chinese medicine composition for treating liver-Yang hyperactivity-type hypertension |
| CN102885973A (en) * | 2012-10-26 | 2013-01-23 | 武美英 | Chinese medicinal decoction for treating hypertension |
| CN104645091A (en) * | 2013-11-25 | 2015-05-27 | 陕西康乐中医药养生研究院 | Capsule for treating hypertension |
| CN105055839A (en) * | 2015-08-18 | 2015-11-18 | 姚良本 | Traditional Chinese medicine composition for treating hypertension and preparation method thereof |
-
2016
- 2016-01-21 CN CN201610040872.XA patent/CN105535636A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526340A (en) * | 2011-12-30 | 2012-07-04 | 辽宁中医药大学附属医院 | Medicament for preventing and treating hypertension |
| CN102698092A (en) * | 2012-06-04 | 2012-10-03 | 蒋月芳 | Traditional Chinese medicine composition for treating liver-Yang hyperactivity-type hypertension |
| CN102885973A (en) * | 2012-10-26 | 2013-01-23 | 武美英 | Chinese medicinal decoction for treating hypertension |
| CN104645091A (en) * | 2013-11-25 | 2015-05-27 | 陕西康乐中医药养生研究院 | Capsule for treating hypertension |
| CN105055839A (en) * | 2015-08-18 | 2015-11-18 | 姚良本 | Traditional Chinese medicine composition for treating hypertension and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 李才顺，杨玉梅: "平降汤治疗110例高血压临床观察", 《河北中医》 * |
| 王强等: "清肝潜阳降压方治疗原发性高血压52例", 《实用临床医学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105726573A (en) * | 2016-05-09 | 2016-07-06 | 林荣波 | Traditional Chinese medicine composition for treating hypertension caused by liver-yang hyperactivity |
| CN109394960A (en) * | 2018-12-27 | 2019-03-01 | 李晓君 | A kind of Chinese medicine composition and preparation method thereof for treating hypertension |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104338062A (en) | Chinese medicinal preparation for treating stomachache and diarrhea | |
| CN104771606A (en) | Traditional Chinese medicine composition for treating insomnia | |
| CN104547496B (en) | A kind of Chinese medicine composition to moisten the lung and relieve the cough and preparation method thereof | |
| CN101095768B (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
| CN103920034A (en) | Traditional Chinese medicine composition for alleviating side effects of chemotherapy of cancer patient and preparation method traditional Chinese medicine composition | |
| CN105535636A (en) | Medicinal composition for treating liver-yang hyperactivity type hypertension | |
| CN104645249B (en) | One kind treats treating coronary heart disease and angina pectoris | |
| CN100553673C (en) | The Chinese patent medicine of treatment chronic pharyngitis | |
| CN102343049B (en) | Chinese medicinal capsules for treating hypertension due to liver-yang hyperactivity | |
| CN104825956A (en) | Medicine for preventing and treating stroke and recovering muscles, bones and joints | |
| CN111388625A (en) | Traditional Chinese medicine composition for regulating and treating blood stasis constitution and preparation and application thereof | |
| CN110478416A (en) | The composition and its preparation method and application for treating rheumatic rheumatoid arthritis | |
| CN103961490A (en) | Compound medicine for treating wind-cold-dampness arthralgia and preparation method thereof | |
| CN105560892A (en) | Pharmaceutical composition for treating liver-kidney yin deficiency type hypertension | |
| CN107638465A (en) | A kind of Chinese medicine composition for treating arthralgia and preparation method thereof | |
| CN101732648B (en) | Medicament for treating nonunion | |
| CN105943924A (en) | Traditional Chinese medicine for treating gallbladder fire exuberance syndrome type multiple gall-stone | |
| CN106728835A (en) | A kind of Chinese medicine for treating diabetes | |
| CN106236873A (en) | A kind of Chinese medicine composition treating disease of stomach | |
| CN104771528A (en) | Traditional Chinese medicine composition for treating urinary calculi | |
| CN105267862A (en) | Traditional Chinese medicine composition for treating ventricular premature beat | |
| CN104758888A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN104491316A (en) | Traditional Chinese medicine preparation for treating middle-warmer energy insufficiency type prostate hyperplasia | |
| CN103735868B (en) | A kind of preparation method of anal and intestinal disease postoperative bag | |
| CN103566302A (en) | Traditional Chinese medicine for treating atrophic gastritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160504 |
|
| RJ01 | Rejection of invention patent application after publication |